Protocols for the measurement of the F2-isoprostane, 15(S)-8-iso-prostaglandin F2α, in biological samples by GC-MS or GC-MS/MS coupled with immunoaffinity column chromatography

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1019, Issue , 2016, Pages 191-201

  Tsikas, Dimitrios ^a   Suchy, Maria Theresia ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biological samples; Immunoaffinity column chromatography; Mass spectrometry; Oxidative stress; Protocols; Stable isotopes

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BIOMARKERS; CHEMICAL ANALYSIS; CHROMATOGRAPHY; ENZYMES; ESTERIFICATION; ESTERS; GAS CHROMATOGRAPHY; IONIZATION OF GASES; ISOTOPES; LIPIDS; MASS SPECTROMETRY; NEGATIVE IONS; NETWORK PROTOCOLS; OXIDATION; OXIDATIVE STRESS; SPECTROMETRY; UNSATURATED FATTY ACIDS;

ANALYTICAL PROTOCOLS; BIOLOGICAL SAMPLES; ELECTRON-CAPTURE NEGATIVE IONS; IMMUNOAFFINITY COLUMNS; QUANTITATIVE DETERMINATIONS; REACTIVE OXYGEN SPECIES; STABLE ISOTOPES; TRIMETHYLSILYL ETHERS;

COLUMN CHROMATOGRAPHY;

8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; PARACETAMOL; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; RESVERATROL; 8-EPI-PROSTAGLANDIN F2ALPHA; PROSTAGLANDIN F2 ALPHA;

ARTICLE; BLOOD SAMPLING; COLUMN CHROMATOGRAPHY; DERIVATIZATION; ELECTRON CAPTURE DETECTION; END STAGE LIVER DISEASE; ESTERIFICATION; HEMOLYSIS; HUMAN; HYDROLYSIS; IMMUNOAFFINITY COLUMN CHROMATOGRAPHY; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MASS FRAGMENTOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RHEUMATIC DISEASE; SYNTHESIS; TANDEM MASS SPECTROMETRY; URINALYSIS; AFFINITY CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; BLOOD; EVALUATION STUDY; PROCEDURES; URINE;

BIOMARKERS; CHROMATOGRAPHY, AFFINITY; DINOPROST; F2-ISOPROSTANES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY;

EID: 84920812140     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2014.12.019     Document Type: Article

References (25)

1. Tsikas D. Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. J. Chromatogr. B 1998, 717:201-245.
2. Schwedhelm E., Benndorf R.A., Böger R.H., Tsikas D. Mass spectrometric analysis of F2-isoprostanes: markers and mediators in human disease. Curr. Pharm. Anal. 2007, 3:39-51.
3. Tsikas D. Quantitative analysis of biomarkers, drugs and toxins in biological samples by immunoaffinity chromatography coupled to mass spectrometry or tandem mass spectrometry: a focused review of recent applications. J. Chromatogr. B 2009, 878:133-148.
4. Giustarini D., Dalle-Donne I., Tsikas D., Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit. Rev. Clin. Lab. Sci. 2009, 46:241-281.
5. Tsikas D., Zoerner A.A. Analysis of eicosanoids by LC-MS/MS and GC-MS/MS: a historical retrospect and a discussion. J. Chromatogr. B 2014, 964:79-88.
6. Vigor C., Bertrand-Michel J., Pinot E., Oger C., Vercauteren J., Le Faouder P., Galano J.-M., Lee J.C.-Y., Durand T. Non-enzymatic lipid oxidation products in biological systems: assessment of the metabolites from polyunsaturated fatty acids. J. Chromatogr. B 2014, 964:65-78.
7. Bauer J., Ripperger A., Frantz S., Ergün S., Schwedhelm E., Benndorf R.A. Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br. J. Pharmacol. 2014, 171:3115-3131.
8. Hage D.S. Survey of recent advances in analytical applications of immunoaffinity chromatography. J. Chromatogr. B 1998, 715:3-28.
9. Tsikas D. Affinity chromatography as a method for sample preparation in gas chromatography/mass spectrometry. J. Biochem. Biophys. Methods 2001, 49:705-731.
10. Guzman N.A., Phillips T.M. Immunoaffinity CE for proteomics studies. Anal. Chem. 2005, 77:61A-67A.
11. Hage D.S., Anguizola J.A., Bi C., Li R., Matsuda R., Papastavros E., Pfaunmiller E., Vargas J., Zheng X. Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments. J. Pharm. Biomed. Anal. 2012, 69:93-105.
12. Bachi A., Zuccato E., Baraldi M., Fanelli R., Chiabrando C. Measurement of urinary 8-Epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry: basal levels in smokers and nonsmokers. Free Radic. Biol. Med. 1996, 20:619-624.
13. Tsikas D., Schwedhelm E., Suchy M.T., Niemann J., Gutzki F.M., Erpenbeck V.J., Hohlfeld J.M., Surdacki A., Frölich J.C. Divergence in urinary 8-iso-PGF(2alpha) (IPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha): possible methodological, mechanistic and clinical implications. J. Chromatogr. B 2003, 794:237-255.
14. Morrow J.D., Roberts L.J. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol. 1999, 300:3-12.
15. Milne G.L., Sanchez S.C., Musiek E.S., Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2007, 2:221-226.
16. Tsikas D. De novo synthesis of trideuteromethyl esters of amino acids for use in GC-MS and GC-tandem MS exemplified for ADMA in human plasma and urine: standardization, validation: comparison and proof of evidence for their aptitude as internal standards. J. Chromatogr. B 2009, 877:2308-2320.
17. Tsikas D., Rode I., Becker T., Nashan B., Klempnauer J., Frölich J.C. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003, 38:1063-1064.
18. Fliser D., Wagner K.K., Loos A., Tsikas D., Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005, 16:1135-1140.
19. Pham V.V., Stichtenoth D.O., Tsikas D. Nitrite correlates with 3-nitrotyrosine but not with the F(2)-isoprostane 15(S)-8-iso-PGF(2alpha) in urine of rheumatic patients. Nitric Oxide 2009, 21:210-215.
20. Schwedhelm E., Bierend A., Maas R., Trinks R., Kom G.D., Tsikas D., Böger R.H. Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. J. Thromb. Haemost. 2010, 8:2662-2670.
21. Dreissigacker U., Suchy M.T., Maassen N., Tsikas D. Human plasma concentrations of malondialdehyde (MDA) and the F2-isoprostane 15(S)-8-iso-PGF(2alpha) may be markedly compromised by hemolysis: evidence by GC-MS/MS and potential analytical and biological ramifications. Clin. Biochem. 2010, 43:159-167.
22. Tsikas D., Suchy M.T., Niemann J., Tossios P., Schneider Y., Rothmann S., Gutzki F.M., Frölich J.C., Stichtenoth D.O. Glutathione promotes prostaglandin H synthase (cyclooxygenase)-dependent formation of malondialdehyde and 15(S)-8-iso-prostaglandin F2α. FEBS Lett. 2012, 586:3723-3730.
23. Trettin A., Böhmer A., Suchy M.T., Probst I., Staerk U., Stichtenoth D.O., Frölich J.C., Tsikas D. Effects of paracetamol on NOS, COX, and CYP activity and on oxidative stress in healthy male subjects, rat hepatocytes, and recombinant NOS. Oxid. Med. Cell. Longev. 2014, 2014:212576.
24. Berbée J.F., Wong M.C., Wang Y., van der Hoorn J.W., Khedoe P.P., van Klinken J.B., Mol I.M., Hiemstra P.S., Tsikas D., Romijn J.A., Havekes L.M., Princen H.M., Rensen P.C. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. J. Nutr. Biochem. 2013, 24:1423-1430.
25. Kayacelebi A.A., Pham V.V., Willers J., Hahn A., Stichtenoth D.O., Jordan J., Tsikas D. Plasma homoarginine (hArg) and asymmetric dimethylarginine (ADMA) in patients with rheumatoid arthritis: is homoarginine a cardiovascular corrective in rheumatoid arthritis: an anti-ADMA?. Int. J. Cardiol. 2014, 176:1129-1131.